Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
Condition: Multiple Myeloma Intervention: Biological: IM21 CART Sponsors: Peking Union Medical College Hospital; Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials